TACR1 and Encephalopathy: Ozcan et al.’s study emphasized the role of central anti-inflammatory changes induced by agomelatine as a potential mechanism of improvement in encephalopathy, increasing total antioxidant capacity, reducing IL-1β mRNA levels in the nucleus accumbens and raphe nucleus, as well as TACR1 mRNA levels in the raphe nucleus, PAG, amygdala, and nucleus accumbens [36].